The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Key Findings in Basic Science This Year Hold Promise for Potential Rheumatology Therapies

Key Findings in Basic Science This Year Hold Promise for Potential Rheumatology Therapies

December 18, 2017 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Dr. Pope underscored several research findings that stood out from the pack in his Year in Review talk.

Dr. Pope underscored several research findings that stood out from the pack in his Year in Review talk.
unoL / shutterstock.com

SAN DIEGO—After sifting through the nitty-gritty of the rheumatic disease literature on basic science, Richard Pope, MD—professor of medicine specializing in rheumatology at Northwestern University Feinberg School of Medicine—underscored several findings he thought stood out from the pack in his Year in Review talk at the 2017 ACR/ARHP Annual Meeting.

You Might Also Like
  • 2017 in Review: Key Findings in Basic Science Highlighted at the ACR/ARHP Annual Meeting
  • 2015 ACR/ARHP Annual Meeting: Therapies that Target Schnurri-3 Hold Promise for Osteoporosis
  • ACR/ARHP Annual Meeting Offers Basic Science Track
Explore This Issue
December 2017
Also By This Author
  • Tell a Convincing Story: Tips from the Experts on How to Secure Research Grants

He reviewed findings from November 2016 through October 2017. These were among the findings he highlighted:

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Microglia & SLE

A study published in Nature offered insight into the way microglia may be playing a role in the central nervous system (CNS) symptoms of systemic lupus erythematosus (SLE).1 These brain cells are responsible for pruning and refining synapses, as well as cleaning up debris, such as amyloid plaque, but in disease, they may become inflamed or overprune.

Researchers looking at microglia in mice with lupus-like disease found that phagocytosis of neurons by microglia was increased in a way that was interferon-alpha-receptor dependent.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

They also showed increased type 1 interferon signaling in the brains of deceased SLE patients.

“Under normal circumstances … microglia are phagocytosing synapses to keep them properly pruned,” Dr. Pope said. “Under the influence of type 1 interferon, you can see that there is increased uptake of this material. So one wonders: Could this be one of the mechanisms for CNS abnormalities in our patients with lupus—lupus fog and other symptoms that we see in our patients?”

In a study published in Nature Communications, researchers first showed that mice developed osteoarthritis when the adenosine receptor A2AR was knocked out. … The findings show potential for a new therapy.

Fli1 & Scleroderma

The transcription factor protein, Fli1, has been of interest in the scleroderma field for years, but in a study published in The Journal of Experimental Medicine, Fli1 was deleted only in epithelial cells.2

Researchers found that mice with keratinocytes in which Fli1 has been deleted develop dermal fibrosis, esophageal fibrosis and interstitial lung disease.

Dr. Pope said, “The really interesting part of this mouse model, to me, is the fact that these mice developed a systemic increase of IL-6 [interleukin 6] in the circulation,” along with antinuclear antibodies and autoantibodies to lung homogenates, which was not seen in control mice from the same litter.

Then researchers looked at medullary thymic epithelial cells (mTECs), which play an important role in self-tolerance. These cells are normally positive for Fli1 and autoimmune regulatory (Aire) proteins. But both are reduced in these cells in mice with Fli1 deleted from keratinocytes.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports Tagged With: 2017 ACR/ARHP Annual Meeting, AC&R, Adenosine, American College of Rheumatology (ACR), findings, mice, microglia, Nature Communications, Osteoarthritis, Research, rheumatologist, rheumatology, science, study, therapyIssue: December 2017

You Might Also Like:
  • 2017 in Review: Key Findings in Basic Science Highlighted at the ACR/ARHP Annual Meeting
  • 2015 ACR/ARHP Annual Meeting: Therapies that Target Schnurri-3 Hold Promise for Osteoporosis
  • ACR/ARHP Annual Meeting Offers Basic Science Track
  • Year in Review: Expert Covers 2017’s Key Clinical Findings

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Patient & Caregiver Resources

Find a rheumatology provider. Learn about your condition and how to live with it. English and Spanish language resources.

View Patient & Caregiver Resources »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)